IL178903A0 - Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions - Google Patents
Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditionsInfo
- Publication number
- IL178903A0 IL178903A0 IL178903A IL17890306A IL178903A0 IL 178903 A0 IL178903 A0 IL 178903A0 IL 178903 A IL178903 A IL 178903A IL 17890306 A IL17890306 A IL 17890306A IL 178903 A0 IL178903 A0 IL 178903A0
- Authority
- IL
- Israel
- Prior art keywords
- arylpiperazines
- sulfamoyl
- prophylaxis
- obesity
- treatment
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57223604P | 2004-05-19 | 2004-05-19 | |
EP04102210 | 2004-05-19 | ||
PCT/EP2005/052281 WO2005110413A2 (en) | 2004-05-19 | 2005-05-18 | Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
IL178903A0 true IL178903A0 (en) | 2007-03-08 |
Family
ID=34969508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL178903A IL178903A0 (en) | 2004-05-19 | 2006-10-26 | Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1750712A2 (ja) |
JP (1) | JP2007538054A (ja) |
CN (1) | CN1997370B (ja) |
AU (1) | AU2005244450B2 (ja) |
BR (1) | BRPI0510137A (ja) |
CA (1) | CA2567166A1 (ja) |
IL (1) | IL178903A0 (ja) |
MX (1) | MXPA06013299A (ja) |
NO (1) | NO20065835L (ja) |
RU (1) | RU2395503C2 (ja) |
WO (1) | WO2005110413A2 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1866298A2 (en) | 2005-03-31 | 2007-12-19 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
AU2007206997B2 (en) * | 2006-01-23 | 2011-11-24 | F. Hoffmann-La Roche Ag | Cyclohexyl sulfonamide derivatives having H3 receptor activity |
US8455432B2 (en) * | 2007-01-25 | 2013-06-04 | Verva Pharmaceuticals Ltd. | Insulin sensitisers and methods of treatment |
BRPI1014668A2 (pt) * | 2009-04-22 | 2016-11-01 | Axikin Pharmaceuticals Inc | antagonistas ccr3 de arilsulfonamida |
RU2445963C2 (ru) * | 2010-07-09 | 2012-03-27 | Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") | Фармацевтическая противодиабетическая композиция |
PT2968316T (pt) | 2013-03-13 | 2019-10-29 | Forma Therapeutics Inc | Derivados de 2-hidroxi-1-{4-[(4-fenilfenil)carbonil]piperazin-1-il}etano-1-ona e compostos relacionados como inibidores da sintase de ácidos gordos (fasn) para o tratamento do cancro |
GB201410817D0 (en) | 2014-06-17 | 2014-07-30 | Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R & D | Therapeutic agents |
TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
CN113382633A (zh) | 2018-10-29 | 2021-09-10 | 福马治疗股份有限公司 | (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2748125A (en) | 1954-04-26 | 1956-05-29 | American Cyanamid Co | 1-substituted-4-sulfamylpiperazine and method of preparing the same |
DE1964441A1 (de) | 1969-01-02 | 1970-07-16 | Sandoz Ag | Mittel zur Bekaempfung von unerwuenschtem Pflanzenwachstum |
US3709677A (en) * | 1969-06-25 | 1973-01-09 | Sandoz Ag | N-substituted sulfamoyl compounds useful as herbicides |
DE4025387A1 (de) | 1990-08-10 | 1992-02-13 | Hoechst Ag | Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als reagenzien |
AU683620B2 (en) | 1992-09-28 | 1997-11-20 | Pfizer Inc. | Substituted pyrimidines for control of diabetic complications |
WO1995009151A1 (en) * | 1993-09-28 | 1995-04-06 | Ciba-Geigy Ag | Acylated sulphonamides as insecticides and acaricides |
TR199901765T2 (xx) * | 1997-01-23 | 1999-10-21 | F.Hoffmann-La Roche Ag | S�lfomid-metalloproteaz inhibit�rleri |
DE10035227A1 (de) | 2000-07-20 | 2002-01-31 | Solvay Pharm Gmbh | Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind |
IL164007A0 (en) | 2002-03-13 | 2005-12-18 | Janssen Pharmaceutica Nv | New inhibitors of histone deacetylase |
CN100386329C (zh) * | 2002-06-06 | 2008-05-07 | 贝林格尔.英格海姆药物公司 | 取代的3-氨基-噻吩并[2,3-b]吡啶-2-羧酸酰胺化合物及其制备方法和用途 |
WO2005005382A2 (en) * | 2003-07-02 | 2005-01-20 | Cytokinetics, Inc. | Compounds, compositions and methods |
AU2005279045B2 (en) | 2004-08-28 | 2009-11-26 | Astrazeneca Ab | Pyrimidine sulphonamide derivatives as chemokine receptor modulators |
-
2005
- 2005-05-18 WO PCT/EP2005/052281 patent/WO2005110413A2/en active Application Filing
- 2005-05-18 EP EP05749492A patent/EP1750712A2/en not_active Withdrawn
- 2005-05-18 RU RU2006144812/04A patent/RU2395503C2/ru not_active IP Right Cessation
- 2005-05-18 CA CA002567166A patent/CA2567166A1/en not_active Abandoned
- 2005-05-18 MX MXPA06013299A patent/MXPA06013299A/es not_active Application Discontinuation
- 2005-05-18 CN CN2005800159695A patent/CN1997370B/zh not_active Expired - Fee Related
- 2005-05-18 JP JP2007517257A patent/JP2007538054A/ja active Pending
- 2005-05-18 AU AU2005244450A patent/AU2005244450B2/en not_active Ceased
- 2005-05-18 BR BRPI0510137-9A patent/BRPI0510137A/pt not_active IP Right Cessation
-
2006
- 2006-10-26 IL IL178903A patent/IL178903A0/en unknown
- 2006-12-18 NO NO20065835A patent/NO20065835L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20065835L (no) | 2007-02-16 |
JP2007538054A (ja) | 2007-12-27 |
EP1750712A2 (en) | 2007-02-14 |
CA2567166A1 (en) | 2005-11-24 |
RU2006144812A (ru) | 2008-06-27 |
WO2005110413A2 (en) | 2005-11-24 |
AU2005244450B2 (en) | 2010-08-19 |
CN1997370B (zh) | 2011-06-01 |
AU2005244450A1 (en) | 2005-11-24 |
BRPI0510137A (pt) | 2007-10-02 |
MXPA06013299A (es) | 2007-02-02 |
RU2395503C2 (ru) | 2010-07-27 |
CN1997370A (zh) | 2007-07-11 |
WO2005110413A3 (en) | 2006-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL178903A0 (en) | Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions | |
ZA200703601B (en) | Medicaments for the treatment or prevention of fibriotic diseases | |
HK1190084A1 (zh) | 用於預防和治療補體相關紊亂的 多肽 | |
EP1534074A4 (en) | POLYTHERAPY FOR THE TREATMENT OF OBESITY | |
HK1108168A1 (en) | Vaccine for prevention and treatment of hiv-infection | |
HUP0401656A3 (en) | Mch antagonists for the treatment of obesity and pharmaceutical compositions containing them | |
IL192025A0 (en) | Novel n-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions | |
GB2418025B (en) | Device for the prevention or treatment of ulcers | |
IL184124A0 (en) | Medicaments for the treatment or prevention of fibrotic diseases | |
ZA200800981B (en) | Use of SDF-1 for the treatment and/or prevention of neurological diseases | |
PT2054045E (pt) | Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento da artrite e da dor | |
HUP0402421A3 (en) | Composition inhibiting matrix-metalloproteinases for the treatment of neoplastic diseases | |
AU2003263760A1 (en) | Methods for the treatment or prevention of obesity | |
AU2002364171A8 (en) | Materials and methods for the treatment or prevention of obesity | |
PL1812797T3 (pl) | Kompozycje i sposoby do leczenia chorób hiperproliferacyjnych i zapobiegania tym chorobom | |
PL375564A1 (en) | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma | |
SI1562577T1 (sl) | Acetyl-L-karnitin za preprečevanje in/ali zdravljenje perifernih nevropatij, induciranih s talidomidom | |
ZA200608918B (en) | Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions | |
HUP0300990D0 (en) | Synergistic combination for the prophylaxis and treatment of diabetes | |
GB2401044B (en) | A composition for use in the treatment or prophylaxis of a skin condition in a subject | |
HU0300989D0 (en) | Pharmaceutical composition for the prophylaxis and treatment of diabetes | |
IL188056A0 (en) | Use of allylmercaptocaptopril for treating or preventing obesity and obesity related diseases | |
EP1890693A4 (en) | USE OF ALLYLMERCAPTOCAPTOPRIL FOR TREATING OR PREVENTING OBESITY AND DISEASES ASSOCIATED WITH OBESITY | |
AU2003266621A8 (en) | Medicinal composition for treatment for or prevention of visceral pain | |
SI1610785T1 (sl) | Farmacevtski kombiniran pripravek za zdravljenje spastiäśnosti in/ali boleäśine |